Aleniglipron Oral GLP-1 Research and FDA Status
Aleniglipron, formerly known as GSBR-1290, is an investigational oral small-molecule GLP-1 receptor agonist being studied for obesity and metabolic disease.

Trial stage
Clinical research includes dose-ranging and pivotal studies. Until regulatory review is completed, efficacy, approved population, final dose, warnings, labeling and commercial availability are not established.
ClinicalTrials.gov aleniglipron study
How W8MD can help now
Patients do not need to wait for a future drug to receive evidence-based care. W8MD can compare currently approved weight-loss medications, nutrition, sleep treatment and non-medication plans using medical history, prior attempts, preferences, coverage and sustainable cost.
Discuss currently available options with W8MD
Brooklyn: 718-946-5500 · Northeast Philadelphia: 215-676-2334
Use the form only for a non-urgent callback request. Do not submit private medical, insurance, financial or other sensitive information.
Status reviewed September 4, 2026. Recheck FDA labeling and ClinicalTrials.gov before relying on this page.

